VolitionRX Ltd (VNRX)
0.5149
-0.04
(-6.87%)
USD |
NYAM |
Mar 26, 16:00
0.52
+0.01
(+0.99%)
Pre-Market: 08:10
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 47.71M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -31.33% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 33.23 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.2234 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 92.25% |
Profile
Edit
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. |
| URL | https://www.volition.com |
| Investor Relations URL | N/A |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Mar. 31, 2025 |
| Last Earnings Release | Nov. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. |
| URL | https://www.volition.com |
| Investor Relations URL | N/A |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Mar. 31, 2025 |
| Last Earnings Release | Nov. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |